The CD33 antibody–drug conjugate (ADC), gemtuzumab ozogamicin, is the only current antibody‐based therapy for AML, after it was reapproved by the FDA in 2017 (Jen et al., 2018). Here, CD33 is linked to acute myeloid leukemia.